Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period (2019-2032), Assesses DelveInsight

Key Takeaways from the Progressive Supranuclear Palsy Market Report Key Takeaways from the Progressive Supranuclear Palsy Market Report Discover which therapies are expected to grab the major progressive supranuclear palsy market share @Progressive Supranuclear Palsy Market Report Progressive Supranuclear Palsy Overview Progressive supranuclear palsy, also known as Steele-Richardson-Olszewski syndrome and Parkinson-plus syndrome, is the most frequent atypical Parkinsonism...

Key Takeaways from the Progressive Supranuclear Palsy Market Report

Discover which therapies are expected to grab the major progressive supranuclear palsy market share @ Progressive Supranuclear Palsy Market Report

Progressive Supranuclear Palsy Overview

Progressive supranuclear palsy, also known as Steele-Richardson-Olszewski syndrome and Parkinson-plus syndrome, is the most frequent atypical Parkinsonism. It is one of a group of disorders known as tauopathies. The exact cause is unknown. It does, however, include the aberrant buildup of tau protein in specific tissues. Brain areas, particularly the basal ganglia, and brainstem, produce aberrant tangles, resulting in cell degeneration.

Progressive supranuclear palsy is difficult to diagnose since its symptoms coincide with those of other movement disorders such as Parkinson's disease, frontotemporal dementia, and corticobasal degeneration. There is no specific test for progressive supranuclear palsy, and diagnosis is mainly based on the presence of specific symptoms, clinical examination, and the elimination of other probable causes. Brain imaging, such as MRI, may also be utilized to support the diagnosis by revealing specific patterns of brain shrinkage. Progressive supranuclear palsy is currently diagnosed using two diagnostic criteria: the MDS-PSP and the NINDS-SPSP.

Progressive Supranuclear Palsy Epidemiology Segmentation

DelveInsight estimates that there were approximately 81K prevalent cases of progressive supranuclear palsy in the 7MM in 2022.

Among the 7MM, the US accounted for the largest diagnosed prevalent progressive supranuclear palsy population contributing nearly 33% to the total diagnosed population in 2022. In contrast, Spain accounted for the least, with approximately 5% share of the total population in 2022.

The progressive supranuclear palsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Progressive Supranuclear Palsy Treatment Market 

There is no cure for progressive supranuclear palsy, and the various treatments merely treat the symptoms. Disease-modifying medicines and treatment recommendations are currently lacking in the progressive supranuclear palsy treatment landscape. While symptomatic therapies are commonly employed, their efficacy is only mild to moderate. Specific therapies may be beneficial because one medicine does not alleviate all of the symptoms of progressive supranuclear palsy. Antiparkinson drugs levodopa and amantadine are commonly used to improve muscle flexibility and balance.

Parkinson's drugs are ineffective; about 20–30% of patients respond adequately to levodopa. Antidepressants, anti-inflammatories, and other medications, in addition to antiparkinson drugs, are used to treat related symptoms and diseases. Furthermore, eye drops are indicated for dry eyes to avoid keratitis, and botulinum toxin injections may help with blepharospasm, dystonia, and retrocollis.

The primary pharmacologic drug utilized for dopaminergic replacement therapy in progressive supranuclear palsy is levodopa (together with a peripheral decarboxylase inhibitor such as carbidopa or benserazide), with a more strong response often seen in the PSP-P subtype. Postural instability is unlikely to respond in PSP-P, although bradykinesia, stiffness, and tremor may be found in any phenotype of progressive supranuclear palsy. According to historical research, 20–30% of pathologically verified PSP patients and 20-40% of clinically diagnosed PSP patients responded favorably to levodopa alone or in combination with another dopaminergic drug (such as amantadine). These responses typically arise early in the disease's progression and last only a few months. Furthermore, levodopa therapies are only undertaken in patients with stiffness, bradykinesia, or impeded daily activities due to tremors.

To know more about progressive supranuclear palsy treatment guidelines, visit @ Progressive Supranuclear Palsy Management 

Progressive Supranuclear Palsy Pipeline Therapies and Key Companies

Learn more about the FDA-approved drugs for progressive supranuclear palsy @ Drugs for Progressive Supranuclear Palsy Treatment 

Progressive Supranuclear Palsy Market Dynamics

The progressive supranuclear palsy market is anticipated to change in the coming years. The updated MDS diagnostic criteria for PSP broaden the disease's clinical spectrum by including disorders indicative of PSP as well as a variety of symptomatic PSP presentations. Moreover, advocacy and support organizations are dedicated to increasing awareness, providing resources, and assisting individuals and families impacted by PSP. In addition, increased research can help us understand progressive supranuclear palsy better, including its underlying mechanisms, risk factors, and potential therapy targets. Furthermore, better imaging and biofluid biomarker research will allow early and accurate diagnostic enrolment of relevant patients who are likely to demonstrate more clear favorable effects in clinical trials.

However, several factors are impeding the growth of the progressive supranuclear palsy market. The scarcity of epidemiological data on disease phenotypes restricts research and clinical health interventions. The disease's diverse phenotype makes diagnosing subtypes of PSP difficult, resulting in diagnostic delays and poor treatment outcomes. Moreover, a probable concern is the failure of multiple drugs in clinical trials, including rasagiline, tideglusib, and davunetide. Furthermore, patients become wheelchair dependent due to frequent falls, which has a severe impact on a patient's quality of life and increases the carer's burden.

Scope of the Progressive Supranuclear Palsy Market Report

Discover more about progressive supranuclear palsy drugs in development @ Progressive Supranuclear Palsy Clinical Trials

Table of Contents

Related Reports

Progressive Supranuclear Palsy Epidemiology Forecast

Progressive Supranuclear Palsy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and progressive supranuclear palsy epidemiology trends.

Progressive Supranuclear Palsy Pipeline

Progressive Supranuclear Palsy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key progressive supranuclear Palsy companies, including Retrotope, Woolsey Pharmaceuticals, UCB, Novartis Pharmaceuticals, EmeraMed, Aquinnah Pharmaceuticals, DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect, among others.

Parkinson's Disease Pipeline

Parkinson's Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others.

Psychosis in Parkinson's and Alzheimer's Disease Market

Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/progressive-supranuclear-palsy-market-growing-at-a-cagr-of-27-7-during-the-study-period-20192032-assesses-delveinsight-301876554.html